Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kit L Shaw

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Science Translational Medicine|August 26, 2011
A tale of two SCIDsKit L Shaw, Donald B Kohn
Journal of Virology|January 29, 2003
Foamy virus envelope glycoprotein is sufficient for particle budding and releaseKit L Shaw, Dirk Lindemann, Mark J Mulligan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 13, 2020
Busulfan Pharmacokinetics in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Gene TherapyKathryn L Bradford, Siyu Liu, Maja Krajinovic, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
Scalable assessment of genome editing off-targets associated with genetic variantsJiecong Lin, My Anh Nguyen, Linda Y Lin, et al.
Nature Communications|March 4, 2025
Cultivated autologous limbal epithelial cell (CALEC) transplantation for limbal tem cell deficiency: a phase I/II clinical trial of the first xenobiotic-free, serum-free, antibiotic-free manufacturing protocol developed in the USUla V Jurkunas, Aaron R Kaufman, Jia Yin, et al.
Science Advances|August 18, 2023
Cultivated autologous limbal epithelial cell (CALEC) transplantation: Development of manufacturing process and clinical evaluation of feasibility and safetyUla V Jurkunas, Jia Yin, Lynette K Johns, et al.
Blood|June 3, 2026
Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in Sickle Cell DiseaseErica B Esrick, Leslie Lehmann, Amy Federico, et al.
Blood|May 11, 2021
Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiencyBryanna Reinhardt, Omar Habib, Kit L Shaw, et al.
The Journal of Clinical Investigation|March 28, 2017
Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiencyKit L Shaw, Elizabeth Garabedian, Suparna Mishra, et al.
Blood|September 13, 2012
Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plansFabio Candotti, Kit L Shaw, Linda Muul, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Science Translational Medicine|August 26, 2011
A tale of two SCIDsKit L Shaw, Donald B Kohn
Journal of Virology|January 29, 2003
Foamy virus envelope glycoprotein is sufficient for particle budding and releaseKit L Shaw, Dirk Lindemann, Mark J Mulligan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 13, 2020
Busulfan Pharmacokinetics in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Gene TherapyKathryn L Bradford, Siyu Liu, Maja Krajinovic, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
Scalable assessment of genome editing off-targets associated with genetic variantsJiecong Lin, My Anh Nguyen, Linda Y Lin, et al.
Nature Communications|March 4, 2025
Cultivated autologous limbal epithelial cell (CALEC) transplantation for limbal tem cell deficiency: a phase I/II clinical trial of the first xenobiotic-free, serum-free, antibiotic-free manufacturing protocol developed in the USUla V Jurkunas, Aaron R Kaufman, Jia Yin, et al.
Science Advances|August 18, 2023
Cultivated autologous limbal epithelial cell (CALEC) transplantation: Development of manufacturing process and clinical evaluation of feasibility and safetyUla V Jurkunas, Jia Yin, Lynette K Johns, et al.
Blood|June 3, 2026
Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in Sickle Cell DiseaseErica B Esrick, Leslie Lehmann, Amy Federico, et al.
Blood|May 11, 2021
Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiencyBryanna Reinhardt, Omar Habib, Kit L Shaw, et al.
The Journal of Clinical Investigation|March 28, 2017
Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiencyKit L Shaw, Elizabeth Garabedian, Suparna Mishra, et al.
Blood|September 13, 2012
Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plansFabio Candotti, Kit L Shaw, Linda Muul, et al.
Pageof 2